AXNX * Stock Overview
A medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Axonics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,227.00 |
| 52 Week High | US$1,227.00 |
| 52 Week Low | US$1,227.00 |
| Beta | 0.82 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXNX * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how AXNX * performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how AXNX * performed against the MX Market.
Price Volatility
| AXNX * volatility | |
|---|---|
| AXNX * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: AXNX *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine AXNX *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 797 | Ray Cohen | www.axonics.com |
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.
Axonics, Inc. Fundamentals Summary
| AXNX * fundamental statistics | |
|---|---|
| Market cap | Mex$72.17b |
| Earnings (TTM) | -Mex$34.36m |
| Revenue (TTM) | Mex$8.21b |
8.8x
P/S Ratio-2,101x
P/E RatioIs AXNX * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXNX * income statement (TTM) | |
|---|---|
| Revenue | US$408.81m |
| Cost of Revenue | US$98.55m |
| Gross Profit | US$310.26m |
| Other Expenses | US$311.97m |
| Earnings | -US$1.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 75.89% |
| Net Profit Margin | -0.42% |
| Debt/Equity Ratio | 0% |
How did AXNX * perform over the long term?
See historical performance and comparison